 |
|
Vestibular Toxic Effects Induced by Once-Daily Aminoglycoside Therapy
Shireesha Dhanireddy, MD;
W. Conrad Liles, MD, PhD;
George A. Gates, MD
Arch Otolaryngol Head Neck Surg. 2005;131:46-48.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Aminoglycosides have been traditionally used for treatment of a broad range of bacterial infections. Use of systemic aminoglycoside therapy has declined in recent years because of associated drug-induced toxic effects, including nephrotoxic and ototoxic effects (both vestibular and sensorineural hearing loss) and neuromuscular blockade. Most health care providers are familiar with the nephrotoxic effects of aminoglycosides and follow established guidelines for prevention. However, 1 of the least recognized and most debilitating category of adverse effects of systemic aminoglycoside therapy are vestibular toxic effects (VTEs). The threshold at which aminoglycosides induce VTEs may vary between individuals; therefore this adverse effect may be difficult to predict.1
Over the past decade, once-daily aminoglycoside therapy, as opposed to conventional 3-times-a-day, divided-dose therapy, has emerged as a treatment strategy to potentially reduce aminoglycoside-related toxic effects.2 The benefits of once-daily dosing include easier use, . . . [Full Text of this Article]
REPORT OF CASES
CASE 1 CASE 2 CASE 3
COMMENT
AUTHOR INFORMATION
Author Affiliations: Division of Allergy and Infectious Diseases, Department of Medicine (Drs Dhanireddy and Liles), Department of Otolaryngology and Head and Neck Surgery (Dr Gates), University of Washington, Seattle.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
